

# Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia

Juhi Ojha<sup>1,2</sup>, Veryan Codd<sup>3,4</sup>, Christopher P. Nelson<sup>3,4</sup>, and Niles J. Samani<sup>3,4</sup>, on behalf of the ENGAGE Consortium Telomere Group; Ivan V. Smirnov<sup>5</sup>, Nils R. Madsen<sup>1</sup>, Helen M. Hansen<sup>1</sup>, Adam J. de Smith<sup>2</sup>, Paige M. Bracci<sup>2</sup>, John K. Wiencke<sup>1,6</sup>, Margaret R. Wrensch<sup>1,6</sup>, Joseph L. Wiemels<sup>1,2,6</sup>, and Kyle M. Walsh<sup>1,7</sup>

## Abstract

**Background:** Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Shorter mean telomere length in leukemic cells has been associated with more aggressive disease. Germline polymorphisms in telomere maintenance genes affect telomere length and may contribute to CLL susceptibility.

**Methods:** We collected genome-wide data from two groups of patients with CLL ( $N = 273$ ) and two control populations ( $N = 5,725$ ). In ancestry-adjusted case-control comparisons, we analyzed eight SNPs in genes definitively associated with inter-individual variation in leukocyte telomere length (LTL) in prior genome-wide association studies: *ACYP2*, *TERC*, *NAF1*, *TERT*, *OBFC1*, *CTC1*, *ZNF208*, and *RTEL1*.

**Results:** Three of the eight LTL-associated SNPs were associated with CLL risk at  $P < 0.05$ , including those near: *TERC* [OR, 1.46; 95% confidence interval (CI), 1.15–1.86;  $P = 1.8 \times 10^{-3}$ ], *TERT* (OR = 1.23; 95% CI, 1.02–1.48;  $P = 0.030$ ), and *OBFC1* (OR,

1.36; 95% CI, 1.08–1.71;  $P = 9.6 \times 10^{-3}$ ). Using a weighted linear combination of the eight LTL-associated SNPs, we observed that CLL patients were predisposed to longer LTL than controls in both case-control sets ( $P = 9.4 \times 10^{-4}$  and 0.032, respectively). CLL risk increased monotonically with increasing quintiles of the weighted linear combination.

**Conclusions:** Genetic variants in *TERC*, *TERT*, and *OBFC1* are associated with both longer LTL and increased CLL risk. Because the human CST complex competes with shelterin for telomeric DNA, future work should explore the role of *OBFC1* and other CST complex genes in leukemogenesis.

**Impact:** A genetic predisposition to longer telomere length is associated with an increased risk of CLL, suggesting that the role of telomere length in CLL etiology may be distinct from its role in disease progression. *Cancer Epidemiol Biomarkers Prev*; 25(7); 1043–9. ©2016 AACR.

## Introduction

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous disease with clinical course ranging from indolent to

highly progressive (1). Currently, several prognostic markers including somatic hypermutation in the immunoglobulin heavy-chain variable region, ZAP70 and CD38 expression, and *TP53/SF3B1/NOTCH1* mutation status are used in combination to estimate disease prognosis (2). Telomere length is also associated with CLL progression, where shorter telomere length is correlated with advanced disease stages, Richter transformation (3), and poor patient prognosis (4).

Telomeres are repetitive DNA sequences that cap and protect chromosomes. Telomeric repeats are lost with each somatic cellular division and, when depleted, future mitoses result in the loss of integral genomic DNA. This induces replicative senescence and apoptosis, limiting the replicative potential of somatic cells (5). If adequate oncogenic mutations are acquired before reaching replicative senescence, unlimited proliferation may follow and cancer may result. Thus, long telomeres may increase the risk of cancer by allowing additional time in which a cell can accumulate mutations before reaching this apoptotic checkpoint (6). Following malignant transformation, leukemic cells that proliferate in the absence of an active mechanism of telomere maintenance (e.g., telomerase reactivation) will continue to experience telomere depletion (7, 8). In such tumors, short telomere length would be expected to associate with more advanced and/or highly proliferative leukemia (9, 10).

<sup>1</sup>Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California.

<sup>2</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. <sup>3</sup>Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom. <sup>4</sup>National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom. <sup>5</sup>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. <sup>6</sup>Institute for Human Genetics, University of California, San Francisco, San Francisco, California. <sup>7</sup>Program in Neurologic Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

**Note:** Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

ENGAGE Consortium Telomere Group: Full lists of members and affiliations appear in the Supplementary Note.

M.R. Wrensch, J.L. Wiemels, and K.M. Walsh codirected this work.

**Corresponding Author:** Kyle M. Walsh, University of California San Francisco, Box 0520, 1450 3rd Street HD475, San Francisco, CA 94143-0520. Phone: 415-476-1627; Fax: 415-502-7411; E-mail: Kyle.Walsh@ucsf.edu

doi: 10.1158/1055-9965.EPI-15-1329

©2016 American Association for Cancer Research.

Telomere length decreases with age, but can be significantly different between individuals of the same age due to genetic and environmental influences (11). Heritable differences in leukocyte telomere length (LTL) are associated with SNPs in eight genes involved in telomere maintenance, including *ACYP2*, *TERC*, *NAF1*, *TERT*, *OBFC1*, *CTC1*, *ZNF208*, and *RTEL1* (12, 13). Genome-wide association studies (GWAS) indicate that inherited SNPs near the telomerase-component genes *TERC* and *TERT* are also associated with increased risk of CLL and implicate telomere biology in leukemia predisposition (14, 15). We therefore hypothesized that inherited variation affecting telomere length may be associated with risk of developing CLL, with the heritable and somatic genetic influences having a net effect on telomere length in tumors.

To determine whether common genetic variants associated with inter-individual variation in telomere length confer risk for CLL, we analyzed eight independent SNPs in 273 patients with CLL and 5,725 controls. These SNPs have previously been definitively associated with inter-individual variation in LTL in a GWAS of 37,684 individuals of European ancestry conducted by the ENGAGE Consortium Telomere Group (12). In addition to single variant analyses, we also constructed a weighted linear combination of subject genotype at the eight SNPs to create a summary score that quantifies genotypic contributions to differences in LTL across patients and controls. Although direct measurement of LTL (e.g., by qPCR) is frequently influenced by differing distributions of potential confounders across patients and controls (e.g., age, sex, chemotherapy), SNP genotypes are present since birth and are not confounded by the effect that these variables may have on both telomere length and cancer risk. In addition, although the effect of individual alleles in telomere maintenance genes may be small, the combined effect of numerous such polymorphisms could potentially be quite large and could help identify the "missing heritability" of cancer (16). This Mendelian randomization approach for examining the relationship between telomere length and cancer risk has been previously applied to glioma, melanoma, and lung adenocarcinoma, but not to hematologic malignancies (17–19).

## Materials and Methods

### Ethics statement

The genome-wide meta-analysis of mean LTL obtained approval by local ethics committees, as previously outlined (12). CLL patients and associated genotype and phenotype data in the discovery analyses were collected by the Mayo Clinic as part of the Eastern Cooperative Oncology Group (ECOG) 2997 trial and accessed through dbGaP Study Accession phs000621.v1.p1 after review and approval by the NCI Data Access Committee (2). CLL patients and associated genotype and phenotype data in the replication analyses were collected by The Dana-Farber Cancer Institute (DFCI) and accessed through dbGaP Study Accession phs000435.v2.p1 after review and approval by the National Human Genome Research Institute (NHGRI) Data Access Committee (1).

### Case-control populations

We assessed genetic variants in telomere-associated genes in two independent CLL case-control study groups. The first group included 215 CLL patients from the ECOG 2997 trial (2) and 3,390 Illumina iControl subjects. ECOG patients had symptom-

atic, untreated CLL as defined by NCI 1996 guidelines (20). The second group included 101 nonoverlapping CLL patients from DFCI and 2,603 controls from the Wellcome Trust Case-Control Consortium (WTCCC; refs. 1, 21). The majority (67%) of DFCI cases were chemotherapy-naïve. Additional case and control data appear in Supplementary Table S1.

### Case-control genotyping and quality control

For ECOG patients, DNA was isolated from peripheral blood, obtained before treatment, and shipped overnight at ambient temperature to a central processing laboratory. Mononuclear cells were isolated using Ficoll density-gradient centrifugation and then processed for DNA. All case and control DNA specimens in discovery analyses were genotyped using either the Illumina HumanCNV370-Duo BeadChip or the Illumina HumanHap550 platform. Samples with call rates <95% were excluded from analysis, as were samples with mismatched reported versus genotyped sex. Although all subjects were of self-reported European ancestry, this was validated using principal components analysis in Eigenstrat (22). Analyzed SNPs had call rates >98% and Hardy-Weinberg equilibrium *P* values >0.001 among controls.

For DFCI patients, DNA samples were obtained from normal tissue via either 5 mm skin punch biopsies or collection of 2 mL of saliva as a source of normal epithelial cells. DNA specimens were genotyped using the Affymetrix 6.0 genotyping array. Genotype data for 2,603 European-ancestry control samples genotyped using the Affymetrix 6.0 genotyping array were downloaded from the WTCCC (21). Subjects showing evidence of non-European ancestry, as well as duplicate samples and related subjects (IBD > 0.125) were excluded from analyses. Genome-wide SNP data were used to ensure there was no overlap between ECOG patients and DFCI patients. SNPs with call rates <98% or HWE *P* value <0.001 (among controls) were excluded.

To ensure that infiltrating tumor DNA from ECOG patients did not bias allele frequencies in SNP analyses of blood-derived specimens, genome-wide allele frequencies from ECOG patients (blood-derived specimens) were compared with those in DFCI patients (skin biopsy or saliva-derived specimens). With the exception of SNPs on 13q, allele frequencies differed by no more than 5% across patient sets, reflecting the relatively low burden of copy-number alterations in CLL and the comparability of the two CLL case populations (23, 24). Importantly, there was no evidence of copy-number alterations or copy-neutral LOH within 250 kb of the eight LTL-associated SNPs, as the most common CLL-associated copy-number alterations are located on chromosomes 11, 13, 17 (loss), and 12 (gain; ref. 25), whereas the LTL-associated SNPs are located on chromosomes 2, 3, 4, 5, 10, 17, 19, and 20. As further evidence, allele frequencies in flow-sorted CLL tumor DNA were nearly identical to those in skin biopsy DNA in the eight LTL-associated gene regions among DFCI subjects (Supplementary Fig. S1).

### SNP imputation

Within the two CLL case-control datasets, we imputed 250 kb regions centered on eight SNPs previously associated with LTL in GWAS (12, 13): rs11125529 (*ACYP2*), rs10936599 (*TERC*), rs7675998 (*NAF1*), rs2736100 (*TERT*), rs9420907 (*OBFC1*), rs3027234 (*CTC1*), rs8105767 (*ZNF208*), and rs755017 (*RTEL1*). The top LTL SNP was directly genotyped on-array for *TERC*, *TERT*, and *OBFC1* among ECOG cases and the iControls, and was imputed for the other five genes. The top

LTL SNP was directly genotyped on-array for *ACYP2*, *TERT*, *OBFC1*, *CTC1*, and *ZNF208* among the DFCI cases and Wellcome Trust controls, and was imputed for the other three genes. Imputation was performed using the Impute2 v2.1.2 software and its standard Markov chain Monte Carlo algorithm and default settings for targeted imputation (26). All 1,000 Genomes Phase I haplotypes were provided as the imputation reference panel (27). All SNPs had imputation quality (info) scores > 0.80 and posterior probabilities > 0.90. Individuals with imputed genotype probabilities < 0.70 were excluded to prevent allele misclassification. Imputation was performed separately for the ECOG/iControl case-control set (Illumina array data) and the DFCI/WTCCC dataset (Affymetrix array data).

### Statistical analyses

For single locus SNP associations, allele frequencies in all CLL patients were compared with those in the pooled control dataset using logistic regression in SNPTESTv2 under an allelic additive model (28), adjusting for the first five ancestry-informative principal components from Eigenstrat and for genotyping array (Illumina vs. Affymetrix). To account for potential errors in imputation, a missing-data likelihood score test was applied to produce standard errors which account for the additional uncertainty inherent in the analysis of imputed genotypes. *P* values < 0.05 were considered nominally significant. Sensitivity analyses were conducted wherein cases were compared only with controls genotyped on the same genotyping platform to account for potential differences in genotyping or imputation across arrays.

To investigate the combined effect of the eight LTL-associated SNPs, we created a weighted linear combination by summing the number of "long LTL" alleles that an individual possesses and weighting each allele by its effect size in data from the ENGAGE Consortium Telomere Group (12). The effect size used for weighting was expressed as the number of additional base pairs of telomere length associated with each allele, adjusted for age and sex, as calculated and previously reported by the ENGAGE Consortium Telomere Group (12, 17). The number of base pairs was used because the model can be interpreted as the relative difference in estimated LTL across individuals. The weighted model assigns a value of "0" to an individual who possesses 0 of the alleles associated with longer LTL, whereas an individual possessing all 16 alleles (two alleles at each of eight SNPs) would have a value of "1215." These differences in genotypically estimated LTL were compared between CLL patients and controls using logistic regression, adjusted for the first five ancestry-informative principal components from Eigenstrat and genotyping array (22). ORs correspond to the change in cancer risk relative to a one SD (131.9 bp) increase in genotypically estimated LTL, with the SD defined among the pooled controls. *P* values < 0.05 were considered statistically significant in both discovery and replication analyses. Associations between LTL and tumor stage were tested using the Spearman rank correlation test. All statistical tests presented in the article are two-sided.

## Results

After excluding samples with poor call rates, duplicate samples, cryptically-related individuals, subjects with non-European ancestry, and subjects with imputed genotype probabilities < 0.70 for one or more of the eight LTL-associated SNPs, a total of 273

CLL patients (179 ECOG, 94 DFCI) and 5,725 controls (3,166 Illumina iControls, 2,559 Wellcome Trust controls) remained for analyses. The weighted linear combination of the 8 LTL-associated SNPs (16 LTL-associated alleles) ranged from a minimum value of 115 bp to a maximum of 1,008 bp. Per a 31 bp/year rate of LTL attrition, this 893 bp difference in genotypically estimated LTL between maximum and minimum values corresponds to an approximately 30-year difference in age-associated telomere attrition. Because the LTL estimates were determined using inherited autosomal SNPs, present since birth, there was no association between the weighted sum and either subject age or sex (Supplementary Fig. S2). The mean value of the weighted sum was similar in both control groups (Illumina iControls = 541 bp, Wellcome Trust controls = 544 bp).

In case-control analyses of the LTL-associated SNPs, the allele associated with longer LTL was associated with increased CLL risk for seven of the eight evaluated SNPs (Fig. 1). For three of these SNPs, this association was nominally significant (*P* < 0.05): rs10936599 in *TERC* [OR, 1.46; 95% confidence interval (CI), 1.15–1.86; *P* =  $1.8 \times 10^{-3}$ ], rs2736100 in *TERT* (OR, 1.23; 95% CI, 1.02–1.48; *P* = 0.030), and a novel association at rs9420907 in *OBFC1* (OR, 1.36; 95% CI, 1.08–1.71; *P* =  $9.6 \times 10^{-3}$ ; Table 1; Fig. 1). In addition, a suggestive association was detected at rs11125529 in *ACYP2* (OR, 1.26; 95% CI, 0.98–1.63; *P* = 0.075).


The weighted linear combination of the 8 LTL-associated SNPs was significantly greater in CLL patients than in controls (582 bp vs. 542 bp; Fig. 2), with each SD increase in genotypically estimated LTL (131.9 bp) associated with a 1.31-fold increase in the odds of CLL (95% CI, 1.15–1.50; *P* =  $4.3 \times 10^{-5}$ ; Fig. 1). Importantly, this statistically significant association was observed in both the ECOG/iControl case-control set (OR, 1.31; 95% CI, = 1.12–1.52; *P* =  $9.4 \times 10^{-4}$ ) and the DFCI/WTCCC case-control set (OR, 1.32; 95% CI, 1.02–1.71; *P* = 0.032; Fig. 2). This provides strong support for both the direction and magnitude of the association. The OR for CLL increased monotonically with increasing quintiles of LTL (Fig. 3). Individuals in the highest LTL quintile had a 2.3-fold increased risk of CLL compared with individuals in the lowest LTL quintile (OR, 2.32; 95% CI, 1.51–3.58; *P* =  $1.3 \times 10^{-4}$ ).

To determine if the association between a genetic predisposition to longer telomeres and increased CLL risk was entirely attributable to the previously reported associations between CLL risk and SNPs in *TERT* and *TERC*, we recalculated the weighted linear combination of the 8 LTL-associated SNPs in patients and controls using only the six SNPs located near genes not previously associated with CLL risk (*ACYP2*, *NAF1*, *OBFC1*, *CTC1*, *ZNF208*, and *RTEL1*). Using this reduced 6-SNP estimate of LTL, CLL patients still had a genetic predisposition to significantly longer LTL than controls (*P* = 0.039; Supplementary Fig. S3).

Previous studies indicate that shorter telomere length in CLL tumors is associated with more aggressive disease. We observed a suggestive inverse association between the weighted linear combination and tumor stage (*P* = 0.081), indicating that a genetic predisposition to shorter LTL may be associated with risk of more aggressive CLL subtypes.

## Discussion

We identify inherited genetic variants in *TERC*, *TERT*, and *OBFC1* that are associated with an increased risk of CLL in case-control analyses. SNPs in these genes have previously been

**Figure 1.**

Forest plot showing the effect of alleles associated with longer leukocyte telomere length on CLL risk. Allelic ORs are plotted with 95% CIs. The overall estimate is for the combined effect of all eight SNPs, where the OR relates to the change in CLL risk for one SD increase in genotypically estimated leukocyte telomere length. ORs are based on combined data from 273 CLL patients and 5,725 controls.

associated with inter-individual variation in LTL (12). By integrating CLL case–control data with data from our previous GWAS of LTL, we observed that CLL risk alleles in *TERC*, *TERT*, and *OBFC1* are associated with longer LTL. Although it has previously been reported that inherited SNPs in *TERC* and *TERT* are associated with CLL risk (14, 15), our analyses identify a potential mechanism through which these SNPs may affect leukemia risk: by increasing an individual's LTL. This is supported by our observation that a genetic predisposition to longer LTL is associated with increased CLL risk, even after removing the contributions of *TERC* and *TERT* SNPs from the model. Although each of the LTL-associated variants explains only a small proportion of the total variance in telomere length across individuals (12), the summary variable made by combining the eight SNPs accounted for a 893-bp difference in LTL. Assuming an annual telomere attrition rate of approximately 30 bp/year in leukocytes, this translates to approximately 30 years of age-related telomere attrition.

Telomere length helps cells to regulate the precipitous balance between mitotic competence and cellular senescence and is influenced by both inherited genetic variants and acquired somatic mutations. In studies where telomere length was measured in CLL tumor cells, shorter telomere length was correlated with more aggressive disease (4, 29, 30). Telomere length in cancer tissue can also be affected by patient age, therapeutic regimen, and the rate of tumor proliferation (31). Our analyses use a Mendelian randomization approach to estimate genotypically determined telomere length in healthy leukocytes, free from the confounding effects of age, sex, therapy, subclinical tumor, or disease aggressiveness. Our results complement a recent case–control study, nested within the EPIC cohort, that directly measured LTL in prediagnostic blood specimens from patients with B-cell lymphoma. Similar to our results, they observed that longer LTL was associated with increased cancer risk (32).

**Table 1.** Results for each telomere length-associated SNP, including effect on telomere length in the ENGAGE Consortium genome-wide meta-analysis and on CLL risk in the pooled CLL case–control dataset

SNP <sup>a</sup>	Chromosome	Gene	Effect allele <sup>b</sup>	Effect on LTL				Effect on CLL risk			
				EAF <sup>c</sup>	Beta	BP <sup>d</sup>	P	EAF <sup>e</sup>	OR <sup>f</sup>	95% CI	P
rs11125529	2	ACYP2	A	14%	0.056	66.9	$4.5 \times 10^{-8}$	13%	1.26	0.98–1.63	0.075
rs10936599	3	TERC	C	75%	0.097	117.3	$2.5 \times 10^{-31}$	76%	1.46	1.15–1.86	$1.8 \times 10^{-3}$
rs7675998	4	NAF1	G	78%	0.074	89.7	$4.3 \times 10^{-16}$	77%	1.01	0.83–1.24	0.90
rs2736100	5	TERT	C	49%	0.078	94.2	$4.4 \times 10^{-19}$	51%	1.23	1.02–1.48	0.030
rs9420907	10	OBFC1	C	14%	0.069	82.8	$6.9 \times 10^{-11}$	14%	1.36	1.08–1.71	$9.6 \times 10^{-3}$
rs3027234	17	CTC1	C	79%	0.021	25.3	0.020	78%	0.97	0.77–1.20	0.75
rs8105767	19	ZNF208	G	29%	0.048	57.6	$1.1 \times 10^{-9}$	29%	1.12	0.92–1.36	0.28
rs755017	20	RTEL1	G	13%	0.062	74.1	$6.7 \times 10^{-9}$	12%	1.01	0.76–1.34	0.96

<sup>a</sup>All SNPs were associated with LTL in a previous GWAS and replicated at  $P < 0.05$  in the ENGAGE Consortium genome-wide meta-analysis (12).


<sup>b</sup>The effect allele is the allele associated with increased leukocyte telomere length.

<sup>c</sup>Effect allele frequency (EAF) calculated in all ENGAGE Consortium subjects ( $N = 37,684$ ).

<sup>d</sup>Base pair (BP) estimates of the per-allele effect on LTL in base pairs calculated from the equivalent age-related attrition in telomere repeat length ratio, as previously described (12).

<sup>e</sup>Effect allele frequency calculated in CLL control subjects.

<sup>f</sup>ORs are for each additional copy of the allele associated with longer LTL, calculated in 273 CLL patients and 5,725 controls. ORs >1.0 indicate that the "long" allele is more common in CLL patients, and the "short" allele is more common in controls.



**Figure 2.** Boxplots of genotypically estimated LTL in CLL patients and controls from the ECOG 2997 trial ( $N = 179$ ), Illumina iControls ( $N = 3,166$ ), CLL patients from the DFCI ( $N = 94$ ), Wellcome Trust controls ( $N = 2,559$ ), and combined analyses (273 CLL patients, 5,725 controls). The vertical dotted line shows the average value in the pooled control sets (542 bp). Crosses show sample mean; center lines show sample medians. Box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range (IQR) from the 25th and 75th percentiles. Outliers are represented by dots. The notches in boxes are defined as  $\pm 1.58 \times \text{IQR}/\sqrt{n}$  and give roughly 95% CIs for sample medians.  $P$  values are adjusted for the first five ancestry-informative principal components and, in the combined analysis, for genotyping platform.


Mendelian randomization is an epidemiologic technique that can elucidate the causality of associations (33). As genotypes of individuals are randomized at birth, such studies can eliminate both exogenous confounding factors and the phenomenon of reverse causation. However, factors like linkage disequilibrium, population stratification, and pleiotropy can affect interpretations of Mendelian randomization studies (34). As we analyzed unlinked SNPs that are located on separate autosomes, it is unlikely that linkage disequilibrium would influence the results. Similarly, biases due to population stratification were likely eliminated by carefully excluding individuals with non-European ancestry and adjusting for principal

components in all analyses. As genetic variation near *TERC* and *TERT* may influence cancer risk independent of its effect on telomere length (35), there remains a possibility that pleiotropy could partially underlie the association between LTL and CLL risk observed in our data. Although our sample size was limited to fewer than 300 cases, we observe statistically significant and extremely concordant effects in both the discovery and replication datasets. Future studies in larger and more ethnically diverse populations appear warranted.

Although an association between CLL risk and both shelterin component genes (*POT1*) and telomerase-component genes (*TERC* and *TERT*) has been previously reported, this is the first report of a significant association between CLL risk and a CST complex gene (*OBFC1*). The human CST complex is encoded by three genes: *CTC1*, *OBFC1*, and *TEN1*. The CST complex competes with shelterin for telomeric DNA and inhibits telomerase-based telomere extension through primer sequestration and physical interaction with the POT1-TPP1 telomerase processivity factor (36). Through binding of the telomerase-extended telomere, CST limits telomerase activity and restricts telomere extension to approximately one event per cell cycle (36).

An association between longer LTL and increased cancer risk was recently observed in glioma, melanoma, and lung adenocarcinoma, where a genetic predisposition to longer telomere length was associated with increased risk of malignancy (17–19). Interestingly, patients diagnosed with CLL are at 2-fold to 4-fold increased risk of developing melanoma (37, 38). Although this increased risk has been primarily attributed to the immunosuppressive effect of CLL, a common genetic etiology involving telomere lengthening may also contribute. Indeed, a common genetic etiology for melanoma and glioma has already been reported, mediated by shared heritable risk variants in *TERC*, *TERT*, and *POT1* (39).

Several studies have focused on identifying the underlying cause of shorter telomere length in leukemic cells. Although a



**Figure 3.** Effect of increasing quintile of genotypically estimated leukocyte telomere length on CLL risk in combined discovery and replication datasets. The ORs are relative to the median (third) quintile. Vertical bars correspond to 95% CIs. Quintiles were defined among controls and ranges were: quintile one (115 bp–432 bp), quintile two (433 bp–512 bp), quintile three (513 bp–582 bp), quintile four (583 bp–652 bp), quintile five (653 bp–1,008 bp). ORs are based on combined data from 273 CLL patients and 5,725 controls.

predisposition to longer telomeres at baseline might provide precancerous cells with additional opportunities to acquire mutations and undergo malignant transformation (6, 40, 41), subsequent telomere attrition in aggressive and highly proliferative tumors could cause leukemic cells to have shorter telomere length than healthy cells (42). This is supported by studies revealing that early-stage CLL (i.e., Binet stage A and Rai stage 0) shows no significant difference between telomere length measured in tumor cells and in healthy cells (7, 29), whereas telomere length is significantly shorter in tumor cells than healthy cells taken from patients with advanced disease (9, 10). Thus, shorter telomere length in tumor cells may be a marker of high-risk CLL in association with increased tumor burden, perhaps due to an increased rate of telomere attrition in highly proliferative tumors (30).

We observe a strong and consistent association between a genetic predisposition to longer LTL and increased risk of CLL, similar to previous results for lung adenocarcinoma, melanoma, and glioma (17–19). Future work is needed to understand the cellular mechanisms underlying this association and to explore the role of *OBFC1* and other CST complex genes in leukemogenesis. These studies of CLL initiation will complement existing knowledge about disease progression and can move the field toward better understanding the breadth of factors involved in CLL biology.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Authors' Contributions

**Conception and design:** M.R. Wrensch, J.L. Wiemels, K.M. Walsh

**Development of methodology:** M.R. Wrensch, K.M. Walsh

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** V. Codd, N.J. Samani, H.M. Hansen, J.K. Wiencke, M.R. Wrensch, K.M. Walsh

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** J. Ojha, V. Codd, C.P. Nelson, I.V. Smirnov, M.R. Wrensch, K.M. Walsh

#### References

- Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. *N Engl J Med* 2011;365:2497–506.
- Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. *J Clin Oncol* 2007;25:799–804.
- Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. *Leukemia* 2009;23:1062–72.
- Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. *Haematologica* 2012;97:56–63.
- Blackburn EH. Walking the walk from genes through telomere maintenance to cancer risk. *Cancer Prev Res (Phila)* 2011;4:473–5.
- Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: Evidence for distinct pathways of gliomagenesis. *Neuro Oncol* 2013;15:1041–7.
- Hoxha M, Fabris S, Agnelli L, Bollati V, Cutrona G, Matis S, et al. Relevance of telomere/telomerase system impairment in early stage

**Writing, review, and/or revision of the manuscript:** J. Ojha, N.J. Samani, N.R. Madsen, H.M. Hansen, A.J. de Smith, P.M. Bracci, J.K. Wiencke, M.R. Wrensch, J.L. Wiemels, K.M. Walsh

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** I.V. Smirnov, H.M. Hansen

**Study supervision:** M.R. Wrensch, J.L. Wiemels, K.M. Walsh

#### Grant Support

The results published here are, in part, based upon data obtained from dbGaP Study Accession: phs000435.v2.p1 "Whole Exome Sequencing of Chronic Lymphocytic Leukemia." This work was supported by the National Human Genome Research Institute (5U54HG003067), the Blavatnik Family Foundation, NCI (5R21CA115043-2), the Howard Hughes Medical Institute, and the Damon-Runyon Cancer Research Foundation (CI-38-07). The results published here are, in part, also based upon data obtained from dbGaP Study Accession: phs000621.v1.p1 "Genome Wide Association Studies in ECOG 2997 Trial." Samples and associated genotype and phenotype data were provided by the Mayo Clinic with funding support provided through a cooperative agreement with NCI grant R01CA132780. This study makes use of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the data is available from [www.wtccc.org.uk](http://www.wtccc.org.uk). Funding for the project was provided by the Wellcome Trust under award 076113 and 085475. Additional controls were accessed from Illumina's iControlDB database. Work at The University of California, San Francisco was supported by the NIH grant numbers: R01CA52689 (to M.R. Wrensch, J.K. Wiencke, J.L. Wiemels, I.V. Smirnov, H.M. Hansen, N.R. Madsen, and P.M. Bracci), P50CA097257 (to K.M. Walsh, J.K. Wiencke, M.R. Wrensch, N.R. Madsen, and J. Ojha), R01CA126831 (to M.R. Wrensch, J.K. Wiencke, and H.M. Hansen), and R01CA139020 (to M.R. Wrensch), The Sontag Foundation (to K.M. Walsh), the UCSF Lewis Chair in Brain Tumor Research (to M.R. Wrensch), the UCSF Robert Magnin Newman Chair in Neuro-Oncology (to J.K. Wiencke), and by donations from families and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and William Martinusen (All authors). Work at University of Leicester was undertaken under the framework of European Union Framework 7 ENGAGE Project HEALTH-F4-2007-201413 (to V. Codd and N.J. Samani). N.J. Samani, V. Codd, and C.P. Nelson are supported by the British Heart Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 19, 2016; revised March 29, 2016; accepted March 31, 2016; published OnlineFirst May 13, 2016.

- chronic lymphocytic leukemia. *Genes Chromosomes Cancer* 2014;53:612–21.
- Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: Evidence for a telomere crisis. *Blood* 2010;116:1899–907.
- Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. *Br J Haematol* 2014;167:214–23.
- Dos Santos P, Panero J, Palau Nagore V, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. *Tumour Biol* 2015;36:8317–24.
- Mirabello L, Yu K, Kraft P, De Vivo I, Hunter DJ, Prescott J, et al. The association of telomere length and genetic variation in telomere biology genes. *Hum Mutat* 2010;31:1050–8.
- Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. *Nat Genet* 2013;45:422–7, 7e1–2.
- Mangino M, Hwang SJ, Spector TD, Hunt SC, Kimura M, Fitzpatrick AL, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. *Hum Mol Genet* 2012;21:5385–94.

14. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nat Genet* 2013;45:868–76.
15. Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. *Nat Genet* 2014;46:56–60.
16. Zaitlen N, Kraft P. Heritability in the genome-wide association era. *Hum Genet* 2012;131:1655–64.
17. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. *Oncotarget* 2015;6:42468–77.
18. Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, et al. The effect on melanoma risk of genes previously associated with telomere length. *J Natl Cancer Inst* 2014;106.
19. Zhang C, Doherty JA, Burgess S, Hung RJ, Lindstrom S, Kraft P, et al. Genetic determinants of telomere length and risk of common cancers: A Mendelian randomization study. *Hum Mol Genet* 2015;24:5356–66.
20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. *Blood* 1996;87:4990–7.
21. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661–78.
22. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006;38:904–9.
23. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. *Blood* 2011;118:3051–61.
24. Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. *Haematologica* 2011;96:1161–9.
25. Ouillette P, Malek S. Acquired genomic copy number aberrations in CLL. *Adv Exp Med Biol* 2013;792:47–86.
26. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* 2009;5:e1000529.
27. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. *Nature* 2010;467:1061–73.
28. Marchini J, Howie B. Genotype imputation for genome-wide association studies. *Nat Rev Genet* 2010;11:499–511.
29. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. *Cancer Res* 1998;58:4918–22.
30. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. *Am J Hematol* 2013;88:647–51.
31. Easton DF, Eeles RA. Genome-wide association studies in cancer. *Hum Mol Genet* 2008;17:R109–15.
32. Hosnijeh FS, Matullo G, Russo A, Guarnera S, Modica F, Nieters A, et al. Prediagnostic telomere length and risk of B-cell lymphoma—Results from the EPIC cohort study. *Int J Cancer* 2014;135:2910–7.
33. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. *Bone Marrow Transplant* 1991;7(Suppl 3):9–12.
34. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. *Eur Heart J* 2014;35:1917–24.
35. De Semir D, Nosrati M, Li S, Kashani-Sabet M. Telomerase: Going beyond the ends. *Cell Cycle* 2007;6:546–9.
36. Chen LY, Redon S, Lingner J. The human CST complex is a terminator of telomerase activity. *Nature* 2012;488:540–4.
37. Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL, et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. *Int J Dermatol* 2015;54:e287–93.
38. Famenini S, Martires KJ, Zhou H, Xavier MF, Wu JJ. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. *J Am Acad Dermatol* 2015;72:78–84.
39. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, et al. Telomere maintenance and the etiology of adult glioma. *Neuro Oncol* 2015;17:1445–52.
40. Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. *Nat Biotechnol* 1996;14:836–9.
41. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. *Nat Genet* 2014;46:731–5.
42. Sellmann L, de Beer D, Bartels M, Opalka B, Nuckel H, Duhren U, et al. Telomeres and prognosis in patients with chronic lymphocytic leukaemia. *Int J Hematol* 2011;93:74–82.